FIRST‐MIND: A PHASE IB, OPEN‐LABEL, RANDOMIZED STUDY TO ASSESS SAFETY OF TAFASITAMAB OR TAFASITAMAB + LENALIDOMIDE IN ADDITION TO R‐CHOP IN PATIENTS WITH NEWLY DIAGNOSED DLBCL. (17th June 2021) - Belada, D; Kopeckova, K; Bergua Burgues, J. M; André, M; Pérez Persona, E; Pichler, P; Klöpfer, P; Brackertz, B; Lohrmann, E; Lahiry, A; Shah, N; Brugger, W; et al.